66
Views
10
CrossRef citations to date
0
Altmetric
Original Research

Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients

, , , , , & show all
Pages 2211-2225 | Published online: 08 Jul 2016

References

  • DelmezJASlatopolskyEHyperphosphatemia: its consequences and treatment in patients with chronic renal diseaseAm J Kidney Dis1992193033171562018
  • WinchesterJFRotellarCGogginsMRobinoDRakowskiTAArgyWPCalcium and phosphate balance in dialysis patientsKidney Int Suppl199341S174S1788320914
  • LevinAThompsonCREthierJLeft ventricular mass index increase in early renal disease: impact of decline in hemoglobinAm J Kidney Dis19993412513410401026
  • HarnettJDKentGMBarrePETaylorRParfreyPSRisk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patientsJ Am Soc Nephrol1994148614908161730
  • LocatelliFCannata-AndiaJDruekeTManagement of disturbances of calcium and phosphate metabolism and chronic renal insufficiency with emphasis on the control of hyperphosphatemiaNephrol Dial Transplant20021772373111981055
  • PadhiDHarrisRClinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochlorideClin Pharmacokinet200948530331119566113
  • DruekeTBModulation and action of the calcium sensing receptorNephrol Dial Transplant200419suppl 5V20V2615284356
  • NaganoNNemethEFFunctional proteins involved in regulation of intracellular Ca(21) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimeticsJ Pharmacol Sci20059735536015781990
  • National Kidney Foundation:K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney DiseaseAm J Kidney Dis200342suppl 3S1S20114520607
  • QuarlesLDCinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney diseaseKidney Int Suppl200568Supplement 96s24s2815954947
  • CunninghamJDaneseMOlsonKKlassenPChertowGEffects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidismKidney Int2005684179316164656
  • KruseAEisenbergerUFreyFMohauptMThe calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidismNephrol Dial Transplant2005201311131415941846
  • YangRFreemanKReinkeCTertiary hyperparathyroidism in kidney transplant recipients: characteristics of patients selected for different treatment strategiesTransplantation201294707622706321
  • GoodmanWHladikGTurnerSThe calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidismJ Am Soc Nephrol2002131017102411912261
  • WüthrichRMartinDBilezikianJThe role of calcimimetics in the treatment of hyperparathyroidismEur J Clin Invest20073791592218036025
  • BallingerAEPalmerSCNistorICraigJCStrippoliGFCalcimimetics for secondary hyperparathyroidism in chronic kidney disease patientsCochrane Database of Syst Rev201412182
  • KuczeraPAdamczakMWięcekASafety and efficiency of treatment with cinacalcet of haemodialysed patients with chronic kidney disease and secondary hyperparathyroidismEndokrynol Pol201364317618123873419
  • LiDShaoLZhouHJiangWZhangWXuYThe efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysisEndocrine2013431687722669774
  • QuarlesLDSherrardDJAdlerSThe calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal diseaseJ Am Soc Nephrol20031457558312595492
  • LafranceJCardinalHLeblancMEffect of cinacalcet availability and formulary listing on parathyroidectomy rate trendsBMC Nephrol20131410023642012
  • WetmoreJGurevichKSpragueSA randomized trial of cinacalcet versus vitamin D analogs as monotherapy in secondary hyperparathyroidism (PARADIGM)Clin J Am Soc Nephrol20151061031104025904755
  • OkadaMTominagaYIzumiKTertiary hyperparathyroidism resistant to cinacalcet treatmentTher Apher Dial201115Suppl 1333721595850
  • GogusevJDuchambonPHoryBDepressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidismKidney Int19975113283368995751
  • FukudaNTanakaHTominagaYFukagawaMKurokawaKSeinoYDecreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patientsJ Clin Invest199392143614428397225
  • KiforOMooreFJWangPReduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidismJ Clin Endocrinol Metab199681159816068636374
  • RotheHMShapiroWBSunWYChouSYCalcium-sensing receptor gene polymorphism Arg990Gly and its possible effect on response to cinacalcet HClPharmacogenet Genomics200515293415864123
  • YanoSSugimotoTKanzawaMAssociation of polymorphic alleles of the calcium-sensing receptor gene with parathyroid hormone secretion in hemodialysis patientsNephron200085431732310940742
  • YokoyamaKShigematsuTTsukadaTCalcium-sensing receptor gene polymorphism affects the parathyroid response to moderate hypercalcemic suppression in patients with end-stage renal diseaseClin Nephrol200257213113511863123
  • ErenPTuranKBerberIThe clinical significance of parathyroid tissue calcium sensing receptor gene polymorphisms and expression levels in end-stage renal disease patientsClin Nephrol200972211412119640368
  • ChudekJKarkoszkaHSchmidt-GaykHRitzEKokotFPlasma parathyroid hormone, phosphatemia and vitamin D receptor genotype: are they interrelated?J Nephrol2000131545810720215
  • YokoyamaKShigematsuTTsukadaTApa I polymorphism in the vitamin D receptor gene may affect the parathyroid response in Japanese with end-stage renal diseaseKidney Int19985324544589461106
  • OzdemirFNSezerSAtacBVitamin D receptor BsmI and TagI gene polymorphisms in a Turkish ESRD population: influences on parathyroid hormone responseTransplant Proc20053772922292416213262
  • Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patientsWolters Kluwer2015 Available from: www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-and-mineral-metabolism-abnormalities-in-dialysis-patients?source=search_result&search=treatment+failure+secondary+hyperparathyroidism&selectedTitle=1~150Accessed December 9
  • CunninghamJLocatelliFRodriguezMSecondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic optionsClin J Am Soc Nephrol2011691392121454719
  • YamauchiMSugimotoTYamaguchiTAssociation of polymorphic alleles of the calcium-sensing receptor gene with the clinical severity of primary hyperparathyroidismClin Endocrinol (Oxf)20015537337911589681
  • FilopantiMVergaUErmeticiFMEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990GlyEur J Endocrinol2012167215716422577108
  • HanGWangONieMClinical phenotypes of Chinese primary hyperparathyroidism patients are associated with the calcium-sensing receptor gene R990G polymorphismEur J Endocrinol2013169562963823946278
  • YokoyamaKShigematsuTKagamiSVitamin D receptor gene polymorphism detected by digestion with Apa I influences the parathyroid response to extracellular calcium in Japanese chronic dialysis patientsNephron200189331532011598396
  • KarkoszkaHChudekJStrzelczykPVitamin D receptor gene polymorphism and the rate of bone loss of the femur neck and lumbar spine in hemodialized patients with chronic renal failurePol Merkur Lekarski19982819920210101442
  • JunJKKimSMAssociation study of fibroblast growth factor 2 and fibroblast growth factor receptors gene polymorphism in Korean ossification of the posterior longitudinal ligament patientsJ Korean Neurosurg Soc20125271322993671
  • GuimarãesJMGuimarãesICDuarteMEPolymorphisms in BMP4 and FGFR1 genes are associated with fracture non-unionJ Ortho Res2013311219711979
  • SakanHNakataniKAsaiOReduced renal α-Klotho expression in CKD patients and its effect on renal phosphate handling and vitamin D metabolismPLoS One201491e8630124466013
  • KestenbaumBGlazerNLKöttgenACommon genetic variants associate with serum phosphorus concentrationJ Am Soc Nephrol20102171223123220558539
  • YasuiTOkadaAUrabeYA replication study for three nephrolithiasis loci at 5q35.3, 7p14.3 and 13q14.1 in the Japanese populationJ Hum Genet20135858859323719187
  • BoronWFBoulpaepELMedical Physiology: A Cellular and Molecular ApproachPhiladelphiaSaunders2012
  • TsuiHWInmanRDReveilleJDTsuFWLAssociation of a TNAP haplotype with ankylosing spondylitisArthritis Rheum200756123424317195227
  • ChengNCaiQFangMNo significant association between genetic polymorphisms in the TNAP gene and ankylosing spondylitis in the Chinese Han populationRheumatol Int200829330531018769922
  • MeirTDurlacherKPanZParathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcriptionKidney Int2014861106111524940803
  • TetradisSBezouglaiaOTsingotjidouAParathyroid hormone induces expression of the nuclear orphan receptor Nurr1 in bone cellsEndocrinology2001142266367011159837
  • NakajimaKTamaiMOkaniwaSHumoral hypercalcemia associated with gastric carcinoma secreting parathyroid hormone: a case report and review of the literatureEndocr J201360555756223303131
  • TenneMMcGuiganFJanssonLGenetic variation in the PTH pathway and bone phenotypes in elderly women: evaluation of PTH, PTHLH, PTHR1 and PTHR2 genesBone200842471972718280230
  • TruongNUde B EdwardesMDPapavasiliouVGoltzmanDKremerRParathyroid hormone-related peptide and survival of patients with cancer and hypercalcemiaAm J Med2003115211512112893397
  • IwaseMTakemiTManabeMNagumoMHypercalcemia upon recurrence of renal cell carcinoma producing parathyroid hormone-related proteinInt J Oral Maxillofac Surg200332217418012729778
  • dbSNP. National Library of Medicine Available from: http://www.ncbi.nlm.nih.gov/snp/Accessed December 9, 2015
  • MiyataTMiyazawaSYasunagaTTwo types of amino acid substitutions in protein evolutionJ Mol Evol1979123219236439147
  • BarrettLWFletcherSWiltonSDRegulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elementsCell Mol Life Sci201269213613363422538991
  • PichonXWilsonLAStoneleyMRNA binding protein/RNA element interactions and the control of translationCurr Protein Pept Sci201213429430422708490
  • LeviRBen DovILavi-MoshayoffVIncreased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: correlation with posttranslational modification of the trans acting factor AUF1J Am Soc Nephrol20061710711216291838
  • GilbertSJWeinerDEGipsonDSPerazellaMATonelliMNational Kidney Foundation’s Primer on Kidney Disease6th edPhiladelphiaElsevier2014
  • LiYAmlingMPirroANormalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets and osteomalacia, but not alopecia in vitamin D receptor ablated miceEndocrinology1998139439143969751523
  • GarnerSPiMTuQQuarlesLRickets in cation sensing receptor deficient mice: an unexpected skeletal phenotypeEndocrinology200114293996400511517179
  • BlockGAThe impact of calcimimetics on mineral metabolism and secondary hyperparathyroidism in end-stage renal diseaseKidney Int Suppl200364Suppl 87S131S13614531786
  • TorresPSUtielFJBPeralesMCSCortésMJGBaldánMMBBañascoVPAnalysis of efficacy and factors that impact the response of secondary hyperparathyroidism to cinacalcet in haemodialysis patientsNefrologia201030444345120651886
  • KimJKKwonYJChoiKHRapid decrease of intact parathyroid hormone could be a predictor of better response to cinacalcet in hemodialysis patientsYonsei Med J201354245346323364981
  • IannazzoSCarsiMChiroliSA cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countriesAppl Health Econ Health Policy201210212713822268372
  • KomabaHMoriwakiKGotoSCost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in JapanAm J Kidney Dis201260226227122445709
  • ConzoGPernaAFSavicaVImpact of parathyroidectomy on cardiovascular outcomes and survival in chronic hemodialysis patients with secondary hyperparathyroidism. A retrospective study of 50 cases prior to the calcimimetics eraBMC Surg201313Suppl 2S2S424268048
  • EVOLVE InvestigatorsChertowGMBlockGAEffect of cinacalcet on cardiovascular disease in patients undergoing dialysisN Engl J Med2012367262482249423121374
  • CharytanCCoburnJWChoncholMCinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysisAm J Kidney Dis200546586715983958
  • ChoncholMLocatelliFAbboudHEA randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysisAm J Kidney Dis20095319720719110359
  • MontenegroJCornagoIGallardoIEfficacy and safety of cinacalcet for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney disease before initiation of regular dialysisNephrology201217263122022934
  • de FranciscoALPiñeraCPalomarRCinacalcet should be used to treat secondary hyperparathyroidism in stage 3–4 chronic kidney diseaseNat Clin Pract Nephrol2008436636718506170
  • CoyneDWCinacalcet should not be used to treat secondary hyperparathyroidism in stage 3–4 chronic kidney diseaseNat Clin Pract Nephrol2008436436518477990
  • Cannata-AndíaJBFernández-MartínJLMineral metabolism: should cinacalcet be used in patients who are not on dialysis?Nat Rev Nephrol2009530730819474823
  • Kalantar-ZadehKKovesdyCPIs it worth correcting hyperparathyroidism if hyperphosphatemia and hypocalcemia worsen? A cinacalcet storyAm J Kidney Dis20095318318819166796
  • ShobackDBilezikianJBinderTGravesTTurnerSPeacockMCalcimimetic AMG 073 normalizes total serum calcium in patients with primary hyperparathyroidism [abstract]J Bone Miner Res200015210
  • IndridasonOSHeathHKhoslaSYohayDAQuarlesLDNon- suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidismKidney Int199650166316718914034
  • LewinEGarfiaBRecioFRodriguezMOlgaardKPersistent downregulation of calcium-sensing receptor mRNA in rat parathyroids when severe secondary hyperparathyroidism is reversed by an isogenic kidney transplantationJ Am Soc Nephrol20021382110211612138143
  • KomabaHNakanishiSFujimoriACinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidismClin J Am Soc Nephrol201052305231420798251
  • MeolaMPetrucciIBarsottiGLong-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidismNephrol Dial Transplant20092498298919181759
  • BlockGMartinKde FranciscoACinacalcet for secondary hyperparathyroidism in patients receiving hemodialysisN Engl J Med2004350151516152515071126